Lymphoma Research Foundation
Balance Sheet
Fiscal Year Start:
Jul 1
Assets in 2024 (Year End)
$42,834,039
Investments
64%
Cash & Equivalents
29%
Receivables (Non-Related)
3%
Other Assets
3%
Prepaid Expenses
<1%
Property, Plant, & Equipment (net)
<1%
Related-Party Receivables
0%
Inventories
0%
Liabilities in 2024 (Year End)
$10,073,192
Grants Payable
79%
Other Liabilities
12%
Payables & Accruals
7%
Deferred Revenue
2%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Assets
2023
2024
Change
Cash & Equivalents
$36,005,288
$12,523,520
-65%
Receivables (Non-Related)
$3,222,919
$1,451,760
-55%
Related-Party Receivables
$0
$0
-
Inventories
$0
$0
-
Prepaid Expenses
$276,411
$365,437
+32%
Investments
$0
$27,312,260
-
Property, Plant, & Equipment (net)
$59,990
$33,483
-44%
Other Assets
$1,497,197
$1,147,579
-23%
Total Assets
$41,061,805
$42,834,039
+4%
Liabilities
2023
2024
Change
Payables & Accruals
$490,081
$720,112
+47%
Grants Payable
$8,551,640
$7,969,260
-7%
Deferred Revenue
$125,000
$191,090
+53%
Tax-Exempt Bond Liabilities
$0
$0
-
Custodial & Escrow Liabilities
$0
$0
-
Notes Payable / Debt (Non-Related)
$0
$0
-
Related-Party Payables
$0
$0
-
Other Liabilities
$1,556,491
$1,192,730
-23%
Total Liabilities
$10,723,212
$10,073,192
-6%
Net assets
2023
2024
Change
Restricted Net Assets
$25,359,504
$24,767,594
-2%
Unrestricted Net Assets
$4,979,089
$7,993,253
+61%
Net assets
2023
2024
Change
Net assets
+$30,338,593
+$32,760,847
+8%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)